BLOOD CANCER SECOND OPINIONS:
RUIJIN HOSPITAL & PEKING UNIVERSITY
Two of Asia's most distinguished haematology centres — leaders in leukaemia, lymphoma, myeloma, and bone marrow transplantation — with access to CAR-T products, novel agents, and trials unavailable outside China.
analyticsAt a Glance
- check_circleRuijin Hospital's haematology department is China's leading research and clinical centre for AML and MDS
- check_circlePeking University People's Hospital (PKUPH) operates Asia's largest allogeneic bone marrow transplant programme
- check_circleBoth centres have published landmark haploidentical transplant protocols that changed global BMT practice
- check_circleCancerFax facilitates international second opinion access at both centres — remote and in-person
Why China's Haematology Centres Are a Unique Second Opinion Resource
Blood cancers — leukaemia, lymphoma, myeloma, and related disorders — are areas where Chinese academic haematology has made disproportionate global contributions, particularly in haploidentical transplantation, AML classification, and the development and approval of novel targeted agents and CAR-T products. The combination of high case volume, strong translational research infrastructure, and access to a uniquely broad portfolio of approved and investigational therapies makes Ruijin Hospital and PKUPH exceptional second opinion destinations.
“The Peking Protocol for haploidentical transplantation is now used worldwide — it was developed and validated at PKUPH. This is what it means to have a world-defining haematology centre.”
Ruijin Hospital: AML and MDS Leadership
Ruijin Hospital's haematology department, led by successive internationally recognised haematologists, has published foundational work on AML classification, all-trans retinoic acid (ATRA) treatment for APL (acute promyelocytic leukaemia), and novel targeted therapies. Its AML and MDS second opinion programme draws international referrals from across Asia, the Middle East, and Europe.
PKUPH: Asia's Largest Transplant Programme
Peking University People's Hospital runs Asia's largest allogeneic stem cell transplant programme — with particular renown for the 'Peking Protocol' of haploidentical transplantation (using T-replete grafts from mismatched family donors), which has made transplant accessible to patients without a fully matched donor.
Ruijin and PKUPH: Key Clinical Numbers
The scale of these haematology programmes defines their depth of subspecialist expertise — particularly for rare and complex blood cancer presentations.
- >1,500Allogeneic transplants per year at PKUPH — Asia's highest volumePKUPH performs over 1,500 allogeneic stem cell transplants annually — the highest volume in Asia. This volume includes a large proportion of haploidentical (mismatched family donor) transplants using the Peking Protocol.
- APL cure rates >90%Ruijin's APL programme — among the world's best published outcomesRuijin Hospital's APL programme using ATRA + arsenic trioxide (ATO) combination was foundational in establishing current global standard of care — cure rates exceeding 90% in early APL are now standard.
- 20+Investigational haematology trials open at Ruijin and PKUPH combinedBetween them, Ruijin and PKUPH run over 20 active investigational trials across AML, CML, ALL, MDS, lymphoma, and myeloma — including first-in-human studies of novel targeted agents not available outside China.
Ruijin vs PKUPH: Subspecialty Strengths by Blood Cancer Type
Understanding which centre has the deepest expertise for your specific blood cancer helps focus the second opinion at the right institution.
| Blood Cancer Type | Ruijin Hospital (Shanghai) | PKUPH (Beijing) | Second Opinion Value |
|---|---|---|---|
| Acute myeloid leukaemia (AML) | ★★★★★ — National reference centre; APL ATRA+ATO pioneers | ★★★★ — Strong; IDH/FLT3 inhibitor access; transplant decision-making | Both excellent — Ruijin preferred for non-transplant AML; PKUPH for transplant AML |
| Acute lymphoblastic leukaemia (ALL) | ★★★★ — Strong adult ALL; CAR-T programme | ★★★★★ — Largest adult ALL + haploidentical transplant programme in Asia | PKUPH preferred for transplant-eligible ALL; both strong for CAR-T eligibility |
| Myelodysplastic syndrome (MDS) | ★★★★★ — Key opinion leader centre; novel agent access | ★★★★ — Strong; SCT decision-making for high-risk MDS | Ruijin preferred for diagnostic and treatment second opinions in MDS |
| Chronic myeloid leukaemia (CML) | ★★★★ — TKI resistance assessment; ponatinib/asciminib access | ★★★★ — Transplant for TKI-resistant CML | Both strong — Ruijin for TKI optimisation; PKUPH for transplant eligibility |
| Lymphoma (DLBCL, HL, NK/T-cell) | ★★★★ — Strong DLBCL and aggressive lymphoma; CAR-T | ★★★★ — Strong; autologous SCT programme; CAR-T | Both excellent for DLBCL; Ruijin slightly stronger for NK/T-cell lymphoma |
| Multiple myeloma | ★★★★ — BCMA CAR-T access; novel agents | ★★★★ — Autologous transplant; BCMA and dual-target CAR-T | Both strong — choice depends on SCT candidacy and CAR-T product preference |
| Aplastic anaemia / bone marrow failure | ★★★ — Adequate | ★★★★★ — World-leading haploidentical transplant for aplastic anaemia | PKUPH clearly preferred for aplastic anaemia — pioneered haploidentical approach |
How CancerFax Facilitates a Blood Cancer Second Opinion in China
Blood cancer second opinions require specific haematological documentation beyond standard oncology records — CancerFax's process is tailored to these requirements.
- 1
Submit Full Haematological Workup
Bone marrow biopsy with H&E and IHC; bone marrow aspirate cytology and cytogenetics (karyotype); FISH panel for relevant targets; flow cytometry with full immunophenotyping; NGS myeloid or lymphoid panel; CBC, LDH, beta-2 microglobulin, serum protein electrophoresis (myeloma), LFTs, and renal function.
- 2
Prior Treatment and Response Records
Complete records of all prior lines — drug names, doses, cycles, response assessment by standard criteria (complete remission, MRD status, best response), duration of response, and reason for stopping.
- 3
Molecular and Cytogenetic Reports
Current and historical karyotype, FISH for high-risk features (del17p, del11q in CLL; MYC/BCL2/BCL6 in DLBCL; complex karyotype in AML/MDS); NGS for actionable mutations (IDH1/2, FLT3, NPM1, TP53, KRAS, etc.).
- 4
Remote Expert Review with Centre Matching
CancerFax identifies whether Ruijin or PKUPH is the stronger match for your diagnosis and arranges a remote case review by the relevant subspecialist team. An English-language preliminary opinion is delivered within 7–14 days.
- 5
In-Person Consultation if Transplant or CAR-T Is Considered
If the remote review identifies transplant candidacy, CAR-T eligibility, or a clinical trial, CancerFax coordinates an in-person visit — including leukapheresis scheduling, pre-transplant workup, and donor search initiation where relevant.
- 6
Chinese Centre Coordination and Follow-up
CancerFax coordinates ongoing communication between the Chinese haematology team and the patient's home haematologist — including treatment plan translation, protocol documentation, and post-treatment surveillance coordination.
What Chinese Haematology Centres Offer That Western Centres May Not
For patients with relapsed or refractory blood cancers, Chinese haematology centres provide specific advantages over Western centres that are clinically consequential — not just cost differentials.
What Chinese Centres Offer
- Haploidentical transplant for patients without a matched donorThe Peking Protocol allows safe haploidentical (half-matched family donor) transplantation — making SCT available to patients who have no fully matched sibling or unrelated donor, and at lower cost than cord blood alternatives.
- China-approved CAR-T products with broader indicationsBCMA+CD19 dual-targeted products, CD22-targeted constructs, and FLT3-targeted investigational CAR-T — all available in China before or instead of Western regulatory approval.
- Novel targeted agents in trial at major centresChina-developed small molecules (IDH1/2 inhibitors, SYK inhibitors, BTK inhibitors with different resistance profiles) are available in Chinese trials years before global approval.
What May Be Limited Outside China
- Matched unrelated donor (MUD) transplants may have longer registry times in AsiaWestern donor registries (NMDP/Be The Match, DKMS) are very large for Caucasian patients but can struggle to find matched donors for patients of South Asian, Middle Eastern, or African ancestry — where haploidentical transplant at PKUPH is a significant advantage.
- CAR-T product breadth more limitedFDA and EMA have approved fewer CAR-T products than China's NMPA — patients who have exhausted eligible products in the West may still have options in China.
- Novel agent clinical trial access may have longer waiting timesFirst-in-class agent trials in haematology often open in the USA or Europe first — but for agents specifically developed by Chinese companies (BeiGene, Zymeworks, Gracell), Chinese centres often have earlier and broader trial access.
Frequently Asked Questions
Common questions about blood cancer second opinions at Ruijin Hospital and PKUPH through CancerFax.
About Blood Cancer Second Opinions in China
Can AML patients access second opinions at Ruijin Hospital?
Yes — AML is Ruijin's strongest subspecialty. The haematology department has particular depth in AML molecular subtyping (NPM1, FLT3-ITD, IDH1/2, CEBPA), treatment optimisation based on molecular response (MRD-guided therapy), and access to IDH inhibitors and FLT3 inhibitors that may not be available or fully optimised at local centres. CancerFax coordinates the records submission and appointment booking process for AML patients at Ruijin.
I have no matched donor for bone marrow transplant — can PKUPH help?
This is one of PKUPH's most important clinical contributions globally. The Peking Protocol for haploidentical transplantation uses T-replete grafts from half-matched family donors (parents, siblings, children) with specific post-transplant prophylaxis — achieving outcomes equivalent to matched unrelated donor transplants in published comparative data. For patients who have been told they cannot have a transplant due to lack of a matched donor, a PKUPH second opinion is specifically indicated.
Are the CAR-T products available at Ruijin and PKUPH the same quality as US products?
Domestically manufactured Chinese CAR-T products (equecabtagene autoleucel, relma-cel, satricabtagene autoleucel) are NMPA-approved based on clinical trial data meeting internationally recognised efficacy and safety standards. Phase III trial data for Chinese BCMA-directed products shows response rates and safety profiles comparable to Western BCMA CAR-T products. CancerFax provides product-specific efficacy and safety data for any Chinese CAR-T product being considered.
How long does a blood cancer second opinion at Ruijin or PKUPH take?
The remote preliminary review phase, coordinated by CancerFax, typically delivers an initial expert opinion within 7–14 days of receiving complete haematological records. If an in-person visit is warranted (for transplant workup, CAR-T leukapheresis, or bone marrow biopsy), the in-person phase at the Chinese centre typically involves 3–7 days. CancerFax provides a complete timeline estimate before any travel is planned.
More from the Cancer Second Opinion Resource Library
Explore related guides on CAR-T access, molecular second opinions, and China centre overviews.
- ↑ Cancer Second Opinion — Complete Guide
- Second Opinions for CAR-T Therapy Eligibility: China vs Western Access
- Cancer Second Opinions in China: Zhongshan, Fudan, and Sun Yat-sen
- The Molecular Second Opinion: NGS, Liquid Biopsy, and Missed Targeted Therapy
- What Is a Cancer Second Opinion and Why Should Every Patient Consider One?
- Remote vs In-Person Cancer Second Opinions: How to Decide
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Request a Blood Cancer Second Opinion at Ruijin or PKUPH
CancerFax coordinates haematology second opinion access at Ruijin Hospital Shanghai and Peking University People's Hospital — managing records preparation, molecular testing review, appointment booking with the relevant subspecialist, and full logistics support for international patients.
This content is for informational purposes only and does not constitute medical advice. A second opinion is a supplementary expert review — your treating haematologist remains responsible for your clinical care.